Bellerophon Therapeutics, Inc.
BLPH · NASDAQ
9/30/2023 | 6/30/2023 | 3/31/2023 | 12/31/2022 | |
|---|---|---|---|---|
| Market Cap | $4,864 | $8,440 | $81,725 | $8,596 |
| - Cash | $4,382 | $10,575 | $15,172 | $6,924 |
| + Debt | $0 | $0 | $8 | $203 |
| Enterprise Value | $482 | -$2,135 | $66,561 | $1,875 |
| Revenue | $0 | $0 | $5,640 | $0 |
| % Growth | – | -100% | – | – |
| Gross Profit | $0 | -$1 | $5,639 | -$4 |
| % Margin | – | – | 100% | – |
| EBITDA | -$2,170 | -$5,258 | $1,480 | -$5,081 |
| % Margin | – | – | 26.2% | – |
| Net Income | -$1,921 | -$5,138 | $2,822 | -$7,433 |
| % Margin | – | – | 50% | – |
| EPS Diluted | -0.16 | -0.42 | 0.27 | -0.78 |
| % Growth | 61.9% | -255.6% | 134.6% | – |
| Operating Cash Flow | -$6,332 | -$4,921 | $3,266 | -$4,352 |
| Capital Expenditures | $0 | $0 | $0 | $0 |
| Free Cash Flow | -$6,332 | -$4,921 | $3,266 | -$4,352 |